Articles On Suda Pharmaceuticals (ASX:SUD)

Title Source Codes Date
Weed week: Cannabis researchers are still split on matters of the heart

As pot-stock aficionados know, investing in cannabis means navigating a labyrinth of regulatory developments which differ by jurisdiction. The latest big name in healthcare to weigh in is the American Heart Association, which this week rele...

Stockhead SUD 3 days ago
10 at 10: These ASX stocks are shooting hoops this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 3 days ago
Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead product ZolpiMist

Proactive Investors SUD 1 week ago
Scopo’s powerplays: Hemp hippies and wellness wonderlands

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

Stockhead SUD 1 week ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the ASX’s key winners and losers on Thursday, July 30. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 783 stocks rose, 532 declined and 7...

Stockhead SUD 1 week ago
Approval for SUDA Pharmaceuticals' ZolpiMist

Perth-based SUDA Pharmaceuticals (ASX:SUD) has announced the TGA has approved its lead product ZolpiMist (zolpidem tartrate) for the treatment of short-term insomnia in adults.

BiotechDispatch SUD 1 week ago
SUDA Reaches Major Milestone with Grant of TGA Approval for ZolpiMistTM, Stock Rallies Above 150%

SUDA Pharmaceuticals Limited (ASX:SUD) soared above 150 per cent to $0.068 on ASX on 29 July 2020, following the announcement regarding grant of Therapeutics Goods Administration’s (TGA) approval for ZolpiMistTM (zolpidem tartrate). Notably...

Kalkine Media SUD 1 week ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the ASX’s key winners and losers on Wednesday, July 29. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 529 stocks rose, 801 declined and...

Stockhead SUD 1 week ago
Suda Pharmaceuticals share price soars 200% on TGA approval

The Suda Pharmaceuticals Ltd (ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administrat...

Motley Fool SUD 1 week ago
SUDA Pharmaceuticals receives TGA approval for ZolpiMist adult insomnia treatment

Perth-based SUDA Pharmaceuticals (ASX: SUD) has received approval from the Therapeutics Goods Administration for its ZolpiMist oral spray to be used in the treatment of short-term adult insomnia. The company has also been approved as a supp...

SmallCaps SUD 1 week ago
10 at 10: These ASX stocks are pollinating this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 1 week ago
Scopo’s powerplays: It just won’t go down!

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Scott Powe...

Stockhead SUD 2 weeks ago
SUDA Seeking Participation in $3.56M Capital Raising, Eyeing development of Anagrelide and OroMist Assets

SUDA Pharmaceuticals Limited (ASX:SUD), the global leader in reformulating and delivering medication via the oral mucosa is seeking shareholders’ support to participate in the capital raising activity announced in early July 2020. On 3rd J...

Kalkine Media SUD 2 weeks ago
10 at 10: These ASX stocks are looking exquisite this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 4 weeks ago
Suda Pharmaceuticals gets coverage from Edison with 13 cents per share valuation

Suda’s lead product ZolpiMist is the oro-mucosal spray version of the blockbuster insomnia drug Ambien, which has 30 million prescriptions written for it in the US annually.

Proactive Investors SUD 1 month ago
SUDA Announces $3.56 Million Capital Raising to Fund Development of its Key Assets

Australia’s oro-mucosal drug delivery leader, SUDA Pharmaceuticals Limited (ASX:SUD) has recently announced a non-renounceable entitlement offer to raise about $3.56 million via issue of ~142 million new ordinary shares in SUDA, at an attra...

Kalkine Media SUD 1 month ago
Japanese Patent Office Accepted SUDA’s Anagrelide Cancer Patent Application; Stock Surged Over 10%

The Japanese Patent Office has accepted Anagrelide cancer patent application, and the patent would now proceed to grant, notified SUDA Pharmaceuticals Ltd (ASX:SUD) in its latest update. The patent “Use of Anagrelide for Treating Cancer” .....

Kalkine Media SUD 2 months ago
SUDA Expects TGA Review Completion for ZolpiMistTM by Q4 2020

SUDA Pharmaceuticals Limited (ASX:SUD), an Australia-based oro-mucosal drug delivery player, notified in its latest update that the Therapeutic Goods Administration (TGA) review for its insomnia drug ZolpiMistTM is expected to be completed...

Kalkine Media SUD 2 months ago
2 ASX shares to build a diversified dividend portfolio

ASX shares can help you build a diversified dividend portfolio. In this coronavirus era, finding those shares that can grow or even just maintain their dividend is very valuable. Just look at shares like National Australia Bank Ltd (ASX: N...

Motley Fool SUD 3 months ago
SUDA’s March Quarter Report Card Out! Let’s Browse Through Key Developments

Oro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) has announced another set of robust quarterly results for the third quarter of FY2020. During the period, the Company made considerable progress in line with the 2020...

Kalkine Media SUD 3 months ago
Suda Pharmaceuticals progresses ZolpiMist™ commercialisation strategy

The company develops oral sprays using its OroMist® technology to reformulate existing pharmaceuticals

Proactive Investors SUD 3 months ago
SUDA Sets Out Steps in Response to COVID-19 Pandemic

In a recent letter to its top shareholders, Perth-based oro-mucosal drug delivery company SUDA Pharmaceuticals Ltd (ASX:SUD) has outlined the steps it is taking amidst COVID-19 pandemic, that has so far infected more than 780,000 people and...

Kalkine Media SUD 4 months ago
Suda Pharmaceuticals outlines COVID-19 steps as it continues "doing deals"

The company recently entered into an exclusive licence agreement with South Korean subsidiary of Mitsubishi Tanabe Pharma Corporation.

Proactive Investors SUD 4 months ago
Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Stockhead SUD 4 months ago
SUDA Continues With its Commercial Buildout of ZolpiMist™, Signed Additional Licence for the product with Mitsubishi Tanabe Pharma Korea

Progressing remarkably with the commercialisation of its insomnia drug ZolpiMistTM, the oro-mucosal drug delivery leader SUDA Pharmaceuticals Limited (ASX:SUD) has signed an additional licence agreement with one of the top Japanese pharmace...

Kalkine Media SUD 4 months ago
Health Kick Podcast: Could oral sprays replace pills as a better means of drug delivery?

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Michael Baker, CEO of Suda Pharmace...

Stockhead SUD 5 months ago
Lens over SUDA’s Operational Highlights in 1H FY20

Continuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to foc...

Kalkine Media SUD 5 months ago
Lens over SUDA’s Operational Highlights in 1H FY20

Continuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to foc...

Kalkine Media SUD 5 months ago
Lens over SUDA’s Operational Highlights in 1H FY20

Continuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to foc...

Kalkine Media SUD 5 months ago
Here’s the bad news some ASX small caps tried to slip past you over Christmas

Few people are at their desks in the week between Christmas and new year, which means it’s a prime dumping period for companies wanting to hide bad news. But there’s always someone who draws the short straw in a newsroom and this year it wa...

Stockhead SUD 7 months ago
Health: Suda sniffs out a Sanofi study for its mouth spray

Viagra mouth spray maker SUDA Pharmaceuticals (ASX:SUD) has talked a multi-billion dollar pharmaceutical company into backing its tech. Sanofi-Aventis has signed a feasibility agreement to test the mouth spray technology with one of its own...

Stockhead SUD 8 months ago
New partnership with feasibility study for SUDA

SUDA Pharmaceuticals (ASX:SUD) has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, a Spanish pharmaceutical company that focuses on nutrition, health and well-being.

BiotechDispatch SUD 8 months ago
Suda Pharmaceuticals to co-develop paediatric consumer market product with Laboratorios Ordesa

A novel product for the consumer paediatric market could soon be developed after drug delivery specialist Suda Pharmaceuticals (ASX: SUD) announced a fully-funded feasibility study and option agreement with Spanish pharmaceutical company La...

SmallCaps SUD 8 months ago
Health: NZ restricts codeine, painkiller stocks celebrate

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

Stockhead SUD 8 months ago
SUDA announces the appointment of new CEO

SUDA Pharmaceuticals (ASX:SUD), a company focused on oro-mucosal drug delivery, has announced the appointment of Dr Michael Baker as its CEO, commencing 2 January 2020.

BiotechDispatch SUD 8 months ago
Health: Fricken lasers shrink ovarian cancer (also look good on sharks)

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

Stockhead SUD 8 months ago
Weed Week: In Thailand you’ll be able to grow cannabis ‘like any other herb’

Thailand has not yet legalised marijuana but pretty soon Thais will not only be able to grow their own plants but they will be allowed to sell them to the government. “In the near future, families will be able to plant cannabis trees in the...

Stockhead SUD 8 months ago
10 at 10: These ASX stocks are on the move this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 8 months ago
10 at 10: These ASX stocks are getting some airtime this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 8 months ago
10 at 10: These ASX stocks are cruising ahead this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 8 months ago
Lunchtime ASX small cap: Who’s being (digitally) resurrected today?

James Dean is returning to the silver screens after a six and a half decade absence. The Rebel Without A Cause star passed away in a car crash in 1955 but he will be starring in the Vietnam War era drama Finding Jack. Of course filmmakers a...

Stockhead SUD 9 months ago
10 at 10: These ASX stocks have hit the gas this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 9 months ago
SUDA Pharmaceuticals inks deal with Cann Pharmaceutical to develop medical cannabis oral spray

Drug delivery specialist SUDA Pharmaceuticals (ASX: SUD) has finalised a deal with medical cannabis company Cann Pharmaceutical Australia that will see the pair develop an oro-mucosal spray to treat drug-resistant epilepsy, melanoma and mot...

SmallCaps SUD 9 months ago
10 at 10: These ASX stocks are off to the races this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 9 months ago
SUDA Pharmaceuticals Proposed Share Consolidation for Effective Capital Structure

Based in the United States and Australia, SUDA Pharmaceuticals Ltd (ASX: SUD) is a leading drug delivery company of the world engaged in the reformulation of existing medications and delivery of drugs via the oral mucosa. To reformulate the...

Kalkine Media SUD 9 months ago
SUDA Prospers Via Drug Delivery Partnerships: A Quick Review of Deals Transacted for ZolpiMistTM

Oro-mucosal drug delivery giant, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the pharmaceutical development of drug delivery technology. To increase bioavailability, the company is reformulating the existing drugs into oral sprays...

Kalkine Media SUD 10 months ago
10 at 10: These ASX stocks are moving and shaking this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 10 months ago
10 at 10: These ASX stocks are off to a flyer this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 10 months ago
10 at 10: These 10 stocks are off to a head start today

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead SUD 10 months ago
Weed Week: The first cannabis cafe just opened in the US, complete with resident ‘flower hosts’

Kicking back at your favourite cafe and smoking a joint is an activity historically associated with pot-friendly cities such as Amsterdam. But as of this week, that right has now been extended to US citizens with the grand opening of Americ...

Stockhead SUD 10 months ago